Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies

Vranic,Semir; Gatalica,Zoran; Wang,Zhao-Yi

doi:10.3892/ol.2011.375

Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies

Authors:
- Semir Vranic
- Zoran Gatalica
- Zhao-Yi Wang
View Affiliations

Affiliations: Department of Pathology, Clinical Center of the University of Sarajevo, Sarajevo BA-71000, Bosnia and Herzegovina, Department of Pathology, Creighton University Medical Center, Omaha, NE, USA
Published online on: August 5, 2011 https://doi.org/10.3892/ol.2011.375
Pages: 1131-1137

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Apocrine carcinoma of the breast has recently been refined through gene expression profiling. Due to various pathological studies, we compared the results with the MDA-MB-453 breast cancer cell line, a proposed model for apocrine breast carcinoma. The MDA-MB-453 cell line is androgen receptor-positive and ‘triple-negative’ in respect to estrogen receptor-α, progesterone receptor and the Her-2/neu protein expression. Cytogenetic analysis of the cell line revealed a hypertriploid clone characterized by extensive numerical and structural abnormalities including loss of the 9p.21 locus (P16-INK4a gene), also evidenced by the lack of p16INK4A protein expression in Western blot analysis and immunocytochemistry assays. Gains of chromosomes 7 and 17 without underlying EGFR, HER-2/neu, and TOP2A gene amplification were also observed. A mutation in the K-RAS gene (Gly13Asp GGC>GAC) was identified in the cell line, which was not observed in the six patient samples of apocrine breast carcinomas examined. Similarly, constitutive activation of the MAPK/ERK signaling pathway and deregulation of cell cycle proteins (p16-/pRb-/cyclin D1+ phenotype) with exceedingly high proliferation observed in the MDA-MB-453 cell line were not found in the tissue samples. In conclusion, the MDA-MB-453 cell line shares certain features with apocrine breast carcinoma but differs from patient tissues with regard to various significant characteristics, limiting the value of this cell line as a model for human apocrine breast carcinoma investigations. In contrast to the cell line, EGFR-positive apocrine carcinomas do not harbor K-RAS gene mutations, rendering these tumors amenable to targeted therapy with EGFR inhibitors.

View Figures

View References

1	Tavassoli FA and Devilee P: World Health Organization Classification of tumours Pathology and genetics of tumours of the breast and female genital organs. IARC Press; Lyon: 2003
2	Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
3	Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI
4	Weigelt B, Horlings HM, Kreike B, et al: Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 216:141–150. 2008. View Article : Google Scholar : PubMed/NCBI
5	Gatalica Z: Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract. 193:753–758. 1997.
6	Tavassoli FA, Purcell CA, Bratthauer GL, et al: Androgen receptor expression along with loss of bcl-2, ER, and PR expression in benign and malignant apocrine lesions of the breast: implications for therapy. Breast J. 2:261–269. 1996. View Article : Google Scholar
7	Bratthauer GL, Lininger RA, Man YH and Tavassoli FA: Androgen and estrogen receptor mRNA status in apocrine carcinomas. Diagn Mol Pathol. 11:113–118. 2002. View Article : Google Scholar : PubMed/NCBI
8	Farmer P, Bonnefoi H, Becette V, et al: Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 24:4660–4671. 2005. View Article : Google Scholar : PubMed/NCBI
9	Burdall SE, Hanby AM, Lansdown MRJ and Speirs V: Breast cancer cell lines: friend or foe? Breast Cancer Res. 5:89–95. 2003. View Article : Google Scholar : PubMed/NCBI
10	Lacroix M and Leclercq G: Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat. 83:249–289. 2004. View Article : Google Scholar : PubMed/NCBI
11	Kao J, Salari K, Bocanegra M, et al: Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One. 4:e61462009.PubMed/NCBI
12	Neve RM, Chin K, Fridlyand J, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515–27. 2006. View Article : Google Scholar : PubMed/NCBI
13	Naderi A and Hughes-Davies L: A functionally significant cross-talk between androgen receptor and erbB2 pathways in estrogen receptor negative breast cancer. Neoplasia. 10:542–548. 2008.
14	Chia KM, Liu J, Francis GD and Naderi A: A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasma. 13:154–66. 2011.PubMed/NCBI
15	De Longueville F, Lacroix M, Barbuto AM, et al: Molecular characterization of breast cancer cell lines by a low-density microarray. Int J Oncol. 27:881–892. 2005.PubMed/NCBI
16	Doane AS, Danso M, Lal P, et al: An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 25:3994–4008. 2006. View Article : Google Scholar
17	Hall RE, Birrell SN, Tilley WD and Sutherland RL: MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. Eur J Cancer. 30A:484–490. 1994. View Article : Google Scholar : PubMed/NCBI
18	Vranic S, Tawfik O, Palazzo J, et al: EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol. 23:644–653. 2010. View Article : Google Scholar : PubMed/NCBI
19	Bhargava R, Beriwal S, Striebel JM and Dabbs DJ: Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR. Appl Immunohistochem Mol Morphol. 18:113–118. 2010. View Article : Google Scholar : PubMed/NCBI
20	Varga Z, Zhao J, Ohlschlegel C, Odermatt B and Heitz PU: Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. Histopathology. 44:332–338. 2004. View Article : Google Scholar : PubMed/NCBI
21	Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z and Wang ZY: A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene. 30:770–780. 2011.
22	Wang Z, Zhang X, Shen P, Loggie BW, Chang Y and Deuel TF: A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA. 103:9063–9068. 2006.
23	Subhawong AP, Subhawong T, Nassar H, et al: Most basal-like breast carcinomas demonstrate the same Rb−/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol. 33:163–75. 2009.PubMed/NCBI
24	Milde-Langosch K, Bamberger AM, Rieck G, Kelp B and Löning T: Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat. 67:61–70. 2001. View Article : Google Scholar : PubMed/NCBI
25	Elayat G, Selim AG and Wells CA: Alterations of the cell cycle regulators cyclin D1, cyclin A, p27, p21, p16, and pRb in apocrine metaplasia of the breast. Breast J. 15:475–482. 2009. View Article : Google Scholar : PubMed/NCBI
26	Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 25:118–145. 2007. View Article : Google Scholar
27	Shaffer LG and Tommerup N: ISCN 2005 An International System for Human Cytogenetic Nomenclature. Karger; Basel: 2005
28	Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J and Gatalica Z: Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer. 117:48–53. 2011. View Article : Google Scholar : PubMed/NCBI
29	Shackelford W, Deng S, Murayama K and Wang J: A new technology for mutation detection. Ann N Y Acad Sci. 1022:257–262. 2004. View Article : Google Scholar : PubMed/NCBI
30	Hollestelle A, Nagel JH, Smid M, et al: Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat. 121:53–64. 2010. View Article : Google Scholar : PubMed/NCBI
31	Arriola E, Marchio C, Tan DS, et al: Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest. 88:491–503. 2008. View Article : Google Scholar : PubMed/NCBI
32	Mackay A, Tamber N, Fenwick K, et al: A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat. 118:481–498. 2009. View Article : Google Scholar : PubMed/NCBI
33	Taniyama K, Ishida K, Toda T, et al: Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas. Breast Cancer. 15:231–240. 2008. View Article : Google Scholar : PubMed/NCBI
34	Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA and Parsons SJ: Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene. 20:1465–1475. 2001. View Article : Google Scholar : PubMed/NCBI
35	Hollestelle A, Elstrodt F, Nagel JHA, Kallemeijn WW and Schutte M: Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Ther. 5:195–201. 2007.PubMed/NCBI
36	Von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE and Boss GR: Ras activation in human breast cancer. Breast Cancer Res Treat. 62:51–62. 2000.PubMed/NCBI
37	Torii S, Yamamoto T, Tsuchiya Y and Nishida E: ERK MAP kinase in G1 cell cycle progression and cancer. Cancer Sci. 97:697–702. 2006. View Article : Google Scholar : PubMed/NCBI
38	Lu Z and Xu S: ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life. 58:621–631. 2006. View Article : Google Scholar : PubMed/NCBI
39	Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
40	McCubrey JA, Steelman LS, Chappell WH, et al: Role of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophysic Acta. 1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
41	Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
42	Capela G, Cronauer-Mitra S, Peinado MA and Perucho M: Frequency and spectrum of mutations at codons 12 and 13 of the C-K-Ras gene in human tumors. Environ Health Perspect. 93:125–131. 1991. View Article : Google Scholar : PubMed/NCBI
43	Myakis S, Sourvinos G and Spandidos DA: Differential expression and mutation of the ras family genes in human breast cancer. Biochem Biophys Res Commun. 251:609–612. 1998. View Article : Google Scholar : PubMed/NCBI
44	Sánchez-Muñoz A, Gallego E, de Luque V, et al: Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer. 10:1362010.PubMed/NCBI
45	Karnoub AE and Weinberg RA: Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 9:517–531. 2008. View Article : Google Scholar : PubMed/NCBI
46	Geradts J and Wilson PA: High frequency of aberrant p16(INK4A) expression in human breast cancer. Am J Pathol. 149:15–20. 1996.PubMed/NCBI
47	Emig R, Magener A, Ehemann V, et al: Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br J Cancer. 78:1661–1668. 1998. View Article : Google Scholar : PubMed/NCBI
48	Di Vinci A, Perdelli L, Banelli B, et al: p16INK4a promoter methylation and protein expression in breast fibroadenoma and carcinoma. Int J Cancer. 114:414–421. 2005.PubMed/NCBI